Literature DB >> 11891301

The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development.

Robyn N McKeller1, Jennifer L Fowler, Justine J Cunningham, Nikita Warner, Richard J Smeyne, Frederique Zindy, Stephen X Skapek.   

Abstract

A key tumor suppressor mechanism that is disrupted frequently in human cancer involves the ARF and p53 genes. In mouse fibroblasts, the Arf gene product responds to abnormal mitogenic signals to activate p53 and trigger either cell cycle arrest or apoptosis. Recent evidence indicates that Arf also has p53-independent functions that may contribute to its tumor suppressor activity. Using Arf(-/-) and p53(-/-) mice, we have discovered a p53-independent requirement for Arf in the developmental regression of the hyaloid vascular system (HVS) in the mouse eye. Arf is expressed in the vitreous of the eye and is induced before HVS regression in the first postnatal week. In the absence of Arf, failed HVS regression causes a pathological process that resembles persistent hyperplastic primary vitreous, a developmental human eye disease thought to have a genetic basis. These findings demonstrate an essential and unexpected role for Arf during mouse eye development, provide insights into the potential genetic basis for persistent hyperplastic primary vitreous, and indicate that Arf regulates vascular regression in a p53-independent manner. The latter finding raises the possibility that Arf may function as a tumor suppressor at least in part by regulating tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891301      PMCID: PMC122612          DOI: 10.1073/pnas.052484199

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival.

Authors:  N Reinmuth; W Liu; Y D Jung; S A Ahmad; R M Shaheen; F Fan; C D Bucana; G McMahon; G E Gallick; L M Ellis
Journal:  FASEB J       Date:  2001-05       Impact factor: 5.191

Review 3.  Vascular-specific growth factors and blood vessel formation.

Authors:  G D Yancopoulos; S Davis; N W Gale; J S Rudge; S J Wiegand; J Holash
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

4.  p53-independent functions of the p19(ARF) tumor suppressor.

Authors:  J D Weber; J R Jeffers; J E Rehg; D H Randle; G Lozano; M F Roussel; C J Sherr; G P Zambetti
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

Review 5.  Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.

Authors:  A Saaristo; T Karpanen; K Alitalo
Journal:  Oncogene       Date:  2000-12-11       Impact factor: 9.867

6.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

7.  Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.

Authors:  L Zhang; D Yu; M Hu; S Xiong; A Lang; L M Ellis; R E Pollock
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

Review 8.  Angiogenesis in cancer and other diseases.

Authors:  P Carmeliet; R K Jain
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

9.  Regulation of mouse lens fiber cell development and differentiation by the Maf gene.

Authors:  B Z Ring; S P Cordes; P A Overbeek; G S Barsh
Journal:  Development       Date:  2000-01       Impact factor: 6.868

10.  Heterogeneity of microvascular pericytes for smooth muscle type alpha-actin.

Authors:  V Nehls; D Drenckhahn
Journal:  J Cell Biol       Date:  1991-04       Impact factor: 10.539

View more
  55 in total

1.  Involvement of Rho family GTPases in p19Arf- and p53-mediated proliferation of primary mouse embryonic fibroblasts.

Authors:  Fukun Guo; Yi Zheng
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

2.  Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice.

Authors:  Haeman Jang; David Boltz; Jennifer McClaren; Amar K Pani; Michelle Smeyne; Ane Korff; Robert Webster; Richard Jay Smeyne
Journal:  J Neurosci       Date:  2012-02-01       Impact factor: 6.167

3.  miR-34a is essential for p19(Arf)-driven cell cycle arrest.

Authors:  Nida Iqbal; Jie Mei; Jing Liu; Stephen X Skapek
Journal:  Cell Cycle       Date:  2014-01-08       Impact factor: 4.534

4.  ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.

Authors:  Suzanne N Brady; Yue Yu; Leonard B Maggi; Jason D Weber
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

5.  Formation of persistent hyperplastic primary vitreous in ephrin-A5-/- mice.

Authors:  Alexander I Son; Michal Sheleg; Margaret A Cooper; Yuhai Sun; Norman J Kleiman; Renping Zhou
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-19       Impact factor: 4.799

6.  p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.

Authors:  Raya Saab; Carlos Rodriguez-Galindo; Kelly Matmati; Jerold E Rehg; Shannon H Baumer; Joseph D Khoury; Catherine Billups; Geoffrey Neale; Kathleen J Helton; Stephen X Skapek
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

Review 7.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

8.  Isolation and characterization of mammalian cells expressing the Arf promoter during eye development.

Authors:  Nida S Iqbal; Lin Xu; Caitlin C Devitt; Stephen X Skapek
Journal:  Biotechniques       Date:  2014-05-01       Impact factor: 1.993

9.  p19Arf represses platelet-derived growth factor receptor β by transcriptional and posttranscriptional mechanisms.

Authors:  Ryan C Widau; Yanbin Zheng; Caroline Y Sung; Anna Zelivianskaia; Lauren E Roach; Karen M Bachmeyer; Tatiana Abramova; Aurelie Desgardin; Andrew Rosner; John M Cunningham; Stephen X Skapek
Journal:  Mol Cell Biol       Date:  2012-08-20       Impact factor: 4.272

10.  Arf tumor suppressor promoter monitors latent oncogenic signals in vivo.

Authors:  Frederique Zindy; Richard T Williams; Troy A Baudino; Jerold E Rehg; Stephen X Skapek; John L Cleveland; Martine F Roussel; Charles J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.